In March 2024, the FDA approved the first over-the-counter continuous glucose monitors (CGMs), marking a quiet but significant shift in how we can track and understand our health. Devices like ...
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. DexCom (NasdaqGS:DXCM) is ...
Dexcom on Tuesday announced its first generative AI feature for its Stelo biosensor that gives users a personalized weekly report about their glucose. The company has been building a generative AI ...
Dexcom, Inc. (Nasdaq:DXCM), the global leader in glucose biosensing, announced it will roll out an advanced AI-enabled enhancement to Stelo that will transform how users understand their glucose ...
The Stelo CGM is meant to give Type 2 diabetics who don’t need insulin a more affordable way to monitor their blood sugar. The Stelo CGM is meant to give Type 2 diabetics who don’t need insulin a more ...
This week, Dexcom became the first medical device company to integrate generative AI into a continuous glucose monitor. The company added generative AI to its Stelo glucose monitor, which it began ...
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. DexCom (NasdaqGS:DXCM) has begun a broad U.S. rollout of ...
Enhanced Smart Food Logging experience now provides nutritional breakdown of meals Advanced AI-enabled features will deliver easy meal tracking to transform daily metabolic health management ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results